Outcomes of Tofacitinib Use in an Irish Pediatric Cohort

BACKGROUND: Pediatric ulcerative colitis (UC) is typically more extensive and severe at diagnosis compared with adult disease. Tofacitinib, a Janus kinase inhibitor, has been used since 2018 to induce and maintain remission in UC. There are limited pediatric data regarding its use, either as a monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Niamh, Cooper, Sarah, Dominik, Anna, Quinn, Shoana, Broderick, Annemarie, Bourke, Billy, Hussey, Séamus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins, Inc. 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435039/
https://www.ncbi.nlm.nih.gov/pubmed/37600624
http://dx.doi.org/10.1097/PG9.0000000000000332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435039/
https://www.ncbi.nlm.nih.gov/pubmed/37600624
http://dx.doi.org/10.1097/PG9.0000000000000332

Ejemplares similares